Completed PHASE3 INTERVENTIONAL 2-arm NCT00502086

Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection.

Efficacy and Safety of Viusid, a Nutritional Supplement, in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection. A Randomized, Controlled and Double Blind Study.

Sponsor: Catalysis SL

Conditions Chronic Hepatitis C Cirrhosis

Interventions Placebo Viusid (nutritional supplement)

Updated 5 times since 2017 Last updated: Feb 10, 2011 Started: May 31, 2005 Primary completion: Jul 31, 2009 Completion: Jul 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Chronic Hepatitis C and Cirrhosis and is currently completed. Catalysis SL leads this study, which shows 5 recorded versions since 2005 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Catalysis SL

Data source: Catalysis SL

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Plaza de la Revolución, Cuba